… use may compromise the clinical efficacy of EGFR-TKIs in … co-medications use in patients
with NSCLC receiving EGFR-TKI … -medications use in NSCLC patients with EGFR mutations in …

… In this study, concurrent use of AS did not … EGFR mutations. It provides data that can guide
expectations for clinicians treating advanced NSCLC patients harboring EGFR mutations with …

… , including the EGFR Thr790Met (T790M) resistance mutation, MET amplification, … EGFR
T790M mutations have been detected in 48–62% of patients that develop resistance to EGFR…

… with EGFR mutations.3, 4 Common toxicities of EGFR TKIs include skin rash, diarrhea, and
nausea, but most are mild in severity and manageable.3, 5 Severe hepatotoxicity involving …

… Potentially inappropriate medication (PIM) use was … analysis to identify factors affecting
multiple-medication use. … is significantly correlated with the BMI, EGFR mutation status, and GRIm-…

… -TKIs are commonly used together with other types of medication that can substantially interact…
the performance therapy and prognosis of patients with advanced EGFR-mutated NSCLC. …

… For patients whose tumors have sensitizing EGFR mutations, EGFR tyrosine kinase … EGFR
TKIs and can encourage open communication with patients about concurrent medication use …

… the possibility to include the list of patient’s medications and to obtain a real-time profile
of … requiring medication, besides anticancer therapies. In addition, patients often use self-…

… AS are also widely used among the general population as over-the-counter medications
to … We identified patients who tested positive for known sensitizing EGFR mutations (EGFRmut …

… treatment strategies in EGFR mutation positive NSCLC with a … Combination use of EGFR
TKIs with checkpoint inhibitors is … that required discontinuation of study medications [36•] (Table …